In receipt of SBIR dollars until 2017 but with website no longer accessible, in a published article by tow of the firm's lead players, Phoenicia BioSciences was described as functioning as a virtual corporation developing therapeutics for hematology-oncology conditions. In the Fall 2018, it was reported that a product was ready to enter clinical trials - reactivation of normal but silenced genes to replace the function of abnormal genes. The firm's lead therapy was described as repurposing of a commercial product in this new indication, with a greatly reduced development path with other products target ing established mechanisms. It was fyrther noted that initiation of a trial in patients was targeted to begin in Q1 2019.
